Single answer
Is ASCENTAGE PHARMA GROUP (AAPG) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for ASCENTAGE PHARMA GROUP INTERNATIONAL is $48.00, which is $22.95 (91.62%) above the current price today's price.
Low target: $45.00 | High target: $51.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Ascentage Pharma Group International a clinicalstage biotechnology company develops therapies for cancers chronic hepatitis B virus HBV and agerelated diseases in Mainland China The companys primary product candidate is HQP1351 a BCRABL inhibitor targeting BCRABL1 mutants including those with the T315I mutation It also develops APG2575 an oral administered Bcl2 selective inhibitor for hematologic malignancies and solid tumors APG115 an oral small molecule inhibitor of the MDM2p53 proteinprotein interactions to treat solid tumors and hematological malignancies and APG1252 a small molecule drug to restore apoptosis through dual inhibition of the Bcl2 and BclxL proteins for the treatment of smallcell lung cancer nonsmall cell lung cancer neuroendocrine tumor and nonHodgkins lymphoma In addition the company is developing APG1387 a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection APG2449 an oral inhibitor of FAK ROS1 and ALK kinases APG5918 an orally available and selective embryonic ectoderm development inhibitor APG265 a MDM2 protein degrader and UBX19671325 which are Bcl2 inhibitors In addition it is also involved in medical research and development clinical development clinical trial operation venture capital investment rental services and science and technology promotion services The company has collaboration relationships with biotechnology and pharmaceutical companies and research institutions Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou China
Website: https://www.ascentage.cn
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.56. Cash flow to debt ratio: 0.14. Net profit margin: -296.77%. Inflation risk score: high (0.85/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
No, the average daily trading liquidity for ASCENTAGE PHARMA GROUP is $152,004. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
10-year return check
We cannot find data for ASCENTAGE PHARMA GROUP 10 years ago, but if you had invested on 2025-01-24 when the price was $17.38, you would have made a profit of $7.67 per share or 44.13%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.